Cardiovascular Considerations in COVID19: A Comprehensive Review

References

• Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. doi:10.1016/S0140-6736(20)30183-5
   PubMed Web of Science ®Google Scholar
• Stöllberger C, Finsterer J. Role of infectious and immune factors in coronary and cerebrovascular arteriosclerosis. Clin Diagn Lab Immunol. 2002;9(2):207–215.
   PubMedGoogle Scholar
• Elkind MS, Harrington RA, Benjamin IJ. Role of the American heart association in the global COVID19 pandemic. Circulation. 2020;141(15). doi:10.1161/CIRCULATIONAHA.120.046749
   Web of Science ®Google Scholar
• Davis MM, Taubert K, Benin AL, et al. Influenza vaccination as secondary prevention for cardiovascular disease: a science advisory from the American Heart Association/American College of Cardiology. J Am Coll Cardiol. 2006;48(7):1498–1502. doi:10.1016/j.jacc.2006.09.004
   PubMed Web of Science ®Google Scholar
• Song Z, Xu Y, Bao L, et al. From SARS to MERS, thrusting coronaviruses into the spotlight. Viruses. 2019;11(1):59. doi:10.3390/v11010059
   PubMed Web of Science ®Google Scholar
• Rajan R, Jarallah M, Dashti R. Cardiovascular complications of novel Wuhan coronavirus (COVID19)–A 2020 update. J Cardiol Curr Res. 2020;13(1):28.
   Google Scholar
• Mattiuzzi C, Lippi G. Which lessons shall we learn from the 2019 novel coronavirus outbreak? Ann Transl Med. 2020;8(3):48. doi:10.21037/atm.2020.02.06
   PubMed Web of Science ®Google Scholar
• Madjid M, Solomon SD, Vardeny O, Mullen B. Cardiac implications of novel coronavirus (COVID19). ACC Clin Bull. 2020.
   Google Scholar
• Xiong T-Y, Redwood S, Prendergast B, Chen M. Coronaviruses and the cardiovascular system: acute and long-term implications. Eur Heart J. 2020;41(19):1798–1800. doi:10.1093/eurheartj/ehaa231
   PubMed Web of Science ®Google Scholar
• Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention. JAMA. 2020;323(13):1239. doi:10.1001/jama.2020.2648
   PubMed Web of Science ®Google Scholar
• Ji D, Zhang D, Xu J, et al. Prediction for progression risk in patients with COVID19 Pneumonia: the CALL score. Clin Infect Dis. 2020;71(6):1393–1399. doi:10.1093/cid/ciaa414
   PubMed Web of Science ®Google Scholar
• Du R-H, Liang L-R, Yang C-Q, et al. Predictors of mortality for patients with COVID19 pneumonia caused by SARS-CoV-2: a prospective cohort study. Eur Respir J. 2020;55(5):2000524. doi:10.1183/13993003.00524-2020
   PubMed Web of Science ®Google Scholar
• Li SS-L, Cheng C-W, Fu C-L, et al. Left ventricular performance in patients with severe acute respiratory syndrome: a 30-day echocardiographic follow-up study. Circulation. 2003;108(15):1798–1803. doi:10.1161/01.CIR.0000094737.21775.32
   PubMed Web of Science ®Google Scholar
• Oudit G, Kassiri Z, Jiang C, et al. SARS‐coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS. Eur J Clin Invest. 2009;39(7):618–625. doi:10.1111/j.1365-2362.2009.02153.x
   PubMed Web of Science ®Google Scholar
• Li F, Li W, Farzan M, Harrison SC. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science. 2005;309(5742):1864–1868. doi:10.1126/science.1116480
   PubMed Web of Science ®Google Scholar
• Chan J, Ng C, Chan Y, et al. Short term outcome and risk factors for adverse clinical outcomes in adults with severe acute respiratory syndrome (SARS). Thorax. 2003;58(8):686–689. doi:10.1136/thorax.58.8.686
   PubMed Web of Science ®Google Scholar
• Yu C, Wong RS, Wu E, et al. Cardiovascular complications of severe acute respiratory syndrome. Postgrad Med J. 2006;82(964):140–144. doi:10.1136/pgmj.2005.037515
   PubMed Web of Science ®Google Scholar
• Yang J, Feng Y, Yuan M, et al. Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS. Diabetic Med. 2006;23(6):623–628. doi:10.1111/j.1464-5491.2006.01861.x
   PubMed Web of Science ®Google Scholar
• Badawi A, Ryoo SG. Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis. Int J Infect Dis. 2016;49:129–133. doi:10.1016/j.ijid.2016.06.015
   PubMed Web of Science ®Google Scholar
• Alhogbani T. Acute myocarditis associated with novel Middle East respiratory syndrome coronavirus. Ann Saudi Med. 2016;36(1):78–80. doi:10.5144/0256-4947.2016.78
   PubMed Web of Science ®Google Scholar
• Arentz M, Yim E, Klaff L, et al. Characteristics and outcomes of 21 critically ill patients with COVID19 in Washington State. JAMA. 2020;323(16):1612. doi:10.1001/jama.2020.4326
   PubMed Web of Science ®Google Scholar
• Lippi G, Lavie CJ, Sanchis-Gomar F. Cardiac troponin I in patients with coronavirus disease 2019 (COVID19): evidence from a meta-analysis. Prog Cardiovasc Dis. 2020;63(3):390–391. doi:10.1016/j.pcad.2020.03.001
   PubMed Web of Science ®Google Scholar
• Chen C, Zhou Y, Wang DW. SARS-CoV-2: a potential novel etiology of fulminant myocarditis. Herz. 2020;1–3.
   PubMed Web of Science ®Google Scholar
• Shi S, Qin M, Shen B, et al. Association of cardiac injury with mortality in hospitalized patients with COVID19 in Wuhan, China. JAMA Cardiol. 2020;5(7):802–810. doi:10.1001/jamacardio.2020.0950
   PubMed Web of Science ®Google Scholar
• Cai J, Xu J, Lin D, et al. A case series of children with 2019 novel coronavirus infection: clinical and epidemiological features. Clin Infect Dis. 2020.
   Web of Science ®Google Scholar
• Nguyen JL, Yang W, Ito K, Matte TD, Shaman J, Kinney PL. Seasonal influenza infections and cardiovascular disease mortality. JAMA Cardiol. 2016;1(3):274–281. doi:10.1001/jamacardio.2016.0433
   PubMed Web of Science ®Google Scholar
• Zheng -Y-Y, Ma Y-T, Zhang J-Y, Xie X. COVID19 and the cardiovascular system. Nat Rev Cardiol. 2020;1–2.
   PubMed Web of Science ®Google Scholar
• Guo T, Fan Y, Chen M, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID19). JAMA Cardiol. 2020;5(7):811–818. doi:10.1001/jamacardio.2020.1017
   PubMed Web of Science ®Google Scholar
• Harris JE, Shah PJ, Korimilli V, Win H. Frequency of troponin elevations in patients with influenza infection during the 2017–2018 influenza season. IJC Heart Vascul. 2019;22:145–147. doi:10.1016/j.ijcha.2018.12.013
   PubMed Web of Science ®Google Scholar
• Chan JF-W, Yuan S, Kok K-H, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395(10223):514–523. doi:10.1016/S0140-6736(20)30154-9
   PubMed Web of Science ®Google Scholar
• Li B, Yang J, Zhao F, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID19 in China. Clin Res Cardiol. 2020;1–8.
   Web of Science ®Google Scholar
• Sakabe M, Yoshioka R, Fujiki A. Sick sinus syndrome induced by interferon and ribavirin therapy in a patient with chronic hepatitis C. J Cardiol Cases. 2013;8(6):173–175. doi:10.1016/j.jccase.2013.08.002
   PubMedGoogle Scholar
• Li B, Yang J, Zhao F, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID19 in China. Clin Res Cardiol. 2020;109(5):531–538. doi:10.1007/s00392-020-01626-9
   PubMed Web of Science ®Google Scholar
• Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–513. doi:10.1016/S0140-6736(20)30211-7
   PubMed Web of Science ®Google Scholar
• Chen C, Zhou Y, Wang DW. SARS-CoV-2: a potential novel etiology of fulminant myocarditis. Herz. 2020;45(3):230–232. doi:10.1007/s00059-020-04909-z
   PubMed Web of Science ®Google Scholar
• Liu R, Ming X, Zhu H, et al. Association of cardiovascular manifestations with in-hospital outcomes in patients with COVID19: a hospital staff data. medRxiv. 2020.
   Google Scholar
• Gao L, Jiang D, Wen X, et al. Prognostic value of NT-proBNP in patients with severe COVID19. medRxiv. 2020.
   Google Scholar
• Chen S, Huang B, Luo D, et al. Pregnant women with new coronavirus infection: a clinical characteristics and placental pathological analysis of three cases. Zhonghua Bing Li Xue Za Zhi. 2020;49:E005–E.
   Google Scholar
• Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–1062. doi:10.1016/S0140-6736(20)30566-3
   PubMed Web of Science ®Google Scholar
• Zhang Y, Cao W, Xiao M, et al. Clinical and coagulation characteristics in 7 patients with critical COVID-2019 pneumonia and acro-ischemia. Zhonghua Xue Ye Xue Za Zhi= Zhonghua Xueyexue Zazhi. 2020;41(4):302–307.
   PubMedGoogle Scholar
• Helms J, Tacquard C, Severac F, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020;1–10.
   Web of Science ®Google Scholar
• Lodigiani C, Iapichino G, Carenzo L, et al. Venous and arterial thromboembolic complications in COVID19 patients admitted to an academic hospital in Milan, Italy. Thromb Res. 2020;191:9–14. doi:10.1016/j.thromres.2020.04.024
   PubMed Web of Science ®Google Scholar
• Bellosta R, Luzzani L, Natalini G, et al. Acute limb ischemia in patients with COVID19 pneumonia. J Vasc Surg. 2020. doi:10.1016/j.jvs.2020.04.483
   PubMed Web of Science ®Google Scholar
• Price LC, McCabe C, Garfield B, Wort SJ. Thrombosis and COVID19 pneumonia: the clot thickens! Eur Respir J. 2020;56(1):2001608. doi:10.1183/13993003.01608-2020
   PubMed Web of Science ®Google Scholar
• Wang T, Chen R, Liu C, et al. Attention should be paid to venous thromboembolism prophylaxis in the management of COVID19. Lancet Haematolo. 2020;7(5):e362–e3. doi:10.1016/S2352-3026(20)30109-5
   PubMed Web of Science ®Google Scholar
• Klok FA, Kruip M, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID19. Thromb Res. 2020;191:145–147. doi:10.1016/j.thromres.2020.04.013
   PubMed Web of Science ®Google Scholar
• Middeldorp S, Coppens M, van Haaps TF, et al. Incidence of venous thromboembolism in hospitalized patients with COVID‐19. J Thromb Haemostas. 2020.
   Web of Science ®Google Scholar
• Klok FA, Kruip M, Van Der Meer N, et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID19: an updated analysis. Thromb Res. 2020.
   Web of Science ®Google Scholar
• Giudicessi JR, Noseworthy PA, Friedman PA, et al., editors. Urgent guidance for navigating and circumventing the QTc-prolonging and torsadogenic potential of possible pharmacotherapies for coronavirus disease 19 (COVID19). Mayo Clin Proc. 2020;95(6):1213–1221. doi:10.1016/j.mayocp.2020.03.024.
   PubMed Web of Science ®Google Scholar
• Driggin E, Madhavan MV, Bikdeli B, et al. Cardiovascular considerations for patients, health care workers, and health systems during the COVID19 pandemic. J Am Coll Cardiol. 2020;75(18):2352–2371. doi:10.1016/j.jacc.2020.03.031
   PubMed Web of Science ®Google Scholar
• Talasaz AH, Kakavand H, Van Tassell B, et al. Cardiovascular complications of COVID19: pharmacotherapy perspective. Cardiovasc Drugs Ther. 2020. doi:10.1007/s10557-020-07037-2
   PubMed Web of Science ®Google Scholar
• Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061–1069. doi:10.1001/jama.2020.1585
   PubMed Web of Science ®Google Scholar
• Bhatla A, Mayer MM, Adusumalli S, et al. COVID19 and cardiac arrhythmias. Heart Rhythm. 2020;17(9):1439–1444. doi:10.1016/j.hrthm.2020.06.016
   PubMed Web of Science ®Google Scholar
• Dherange P, Lang J, Qian P, et al. Arrhythmias and COVID19: a review. JACC: Clin Electrophysiol. 2020.
   Google Scholar
• Du Y, Tu L, Zhu P, et al. Clinical features of 85 fatal cases of COVID19 from Wuhan. a retrospective observational study. Am J Respir Crit Care Med. 2020;201(11):1372–1379. doi:10.1164/rccm.202003-0543OC
   PubMed Web of Science ®Google Scholar
• Kir D, Mohan C, Sancassani R. Heart brake: an unusual cardiac manifestation of COVID19. JACC: Case Rep. 2020;2(9):1252–1255.
   PubMedGoogle Scholar
• Corrales-Medina VF, Alvarez KN, Weissfeld LA, et al. Association between hospitalization for pneumonia and subsequent risk of cardiovascular disease. JAMA. 2015;313(3):264–274. doi:10.1001/jama.2014.18229
   PubMed Web of Science ®Google Scholar
• Wu Q, Zhou L, Sun X, et al. Altered lipid metabolism in recovered sars patients twelve years after infection. Sci Rep. 2017;7(1):1–12.
   PubMed Web of Science ®Google Scholar
• Turner AJ, Hiscox JA, Hooper NM. ACE2: from vasopeptidase to SARS virus receptor. Trends Pharmacol Sci. 2004;25(6):291–294. doi:10.1016/j.tips.2004.04.001
   PubMed Web of Science ®Google Scholar
• Vickers C, Hales P, Kaushik V, et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem. 2002;277(17):14838–14843. doi:10.1074/jbc.M200581200
   PubMed Web of Science ®Google Scholar
• Serfozo P, Wysocki J, Gulua G, et al. Ang II (Angiotensin II) conversion to angiotensin-(1-7) in the circulation is POP (Prolyloligopeptidase)-dependent and ACE2 (angiotensin-converting enzyme 2)-independent. Hypertension (Dallas, Tex: 1979). 2020;75(1):173–182. doi:10.1161/HYPERTENSIONAHA.119.14071
   PubMed Web of Science ®Google Scholar
• Zheng -Y-Y, Ma Y-T, Zhang J-Y, Xie X. COVID19 and the cardiovascular system. Nat Rev Cardiol. 2020;17(5):259–260. doi:10.1038/s41569-020-0360-5
   PubMed Web of Science ®Google Scholar
• Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin–angiotensin–aldosterone system inhibitors in patients with COVID19. N Engl J Med. 2020;382(17):1653–1659. doi:10.1056/NEJMsr2005760
   PubMed Web of Science ®Google Scholar
• Gurwitz D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev Res. 2020;81(5):537–540. doi:10.1002/ddr.21656
   PubMed Web of Science ®Google Scholar
• Liu Y, Yang Y, Zhang C, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci. 2020;63(3):364–374. doi:10.1007/s11427-020-1643-8
   PubMed Web of Science ®Google Scholar
• Kuba K, Imai Y, Rao S, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med. 2005;11(8):875–879. doi:10.1038/nm1267
   PubMed Web of Science ®Google Scholar
• Cardiology ESo. Position statement of the ESC Council on Hypertension on ACE-inhibitors and angiotensin receptor blockers. ESC. 2020.
   Google Scholar
• Kuster GM, Pfister O, Burkard T, et al. SARS-CoV2: should inhibitors of the renin–angiotensin system be withdrawn in patients with COVID19? Eur Heart J. 2020;41(19):1801–1803. doi:10.1093/eurheartj/ehaa235
   PubMed Web of Science ®Google Scholar
• Madjid M, Casscells SW. Of birds and men: cardiologists’ role in influenza pandemics. Lancet. 2004;364(9442):1309. doi:10.1016/S0140-6736(04)17176-6
   PubMed Web of Science ®Google Scholar
• Xu H, Hou K, Xu H, et al. Acute myocardial injury of patients with coronavirus disease 2019. medRxiv. 2020.
   Google Scholar
• Zeng J, Huang J, Pan L. How to balance acute myocardial infarction and COVID19: the protocols from Sichuan Provincial People’s Hospital. Intensive Care Med. 2020;1–3.
   Web of Science ®Google Scholar
• Welt FG, Shah PB, Aronow HD, et al. Catheterization laboratory considerations during the coronavirus (COVID19) pandemic: from ACC’s interventional council and SCAI. J Am Coll Cardiol. 2020;75(18):2372–2375. doi:10.1016/j.jacc.2020.03.021
   PubMed Web of Science ®Google Scholar
• Bai Y, Yao L, Wei T, et al. Presumed asymptomatic carrier transmission of COVID19. JAMA. 2020;323(14):1406. doi:10.1001/jama.2020.2565
   PubMed Web of Science ®Google Scholar
• Libby P, Simon DI. Inflammation and thrombosis: the clot thickens. Am Heart Assoc. 2001.
   PubMedGoogle Scholar